Regulation of cell death and survival by resveratrol: Implications for cancer therapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 8, 2012, Pages 874-879

  Fulda, Simone ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Apoptosis; Cancer; Cancer therapy; Resveratrol; Signaling

Indexed keywords

BATABULIN; CASPASE 3; CASPASE 7; CASPASE 9; CYCLOOXYGENASE 2; CYTOCHROME C; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR; FAS ANTIGEN; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; INTERLEUKIN 1BETA; MITOCHONDRIAL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN P21; PROTEIN S6; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; RESVERATROL; SILENT INFORMATION REGULATOR PROTEIN 2; SIRTUIN 1; STAT3 PROTEIN; SURVIVIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CHEMOPROPHYLAXIS; CROSS LINKING; DOWN REGULATION; ENDOMETRIUM CARCINOMA; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; INTRACELLULAR SIGNALING; LIVER CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL TARGETING SIGNAL; MULTIPLE MYELOMA; NEOPLASM; NONHODGKIN LYMPHOMA; OLIGOMERIZATION; PANCREAS CANCER; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SKIN CARCINOGENESIS; STRUCTURE ACTIVITY RELATION; UPREGULATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BIOLOGICAL PRODUCTS; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; NEOPLASMS; STILBENES;

EID: 84866416684     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012802650129     Document Type: Article

References (82)

1. Lockshin, R.A.; Zakeri, Z. Cell death in health and disease. J. Cell Mol. Med., 2007, 11(6), 1214-1224.
2. Fulda, S.; Debatin, K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene, 2006, 25(34), 4798-4811.
3. Fulda, S.; Debatin, K.M. Apoptosis signaling pathways in anticancer therapy. Curr. Cancer Ther. Rev., 2008, 4, 14-20.
4. Fulda, S. Tumor resistance to apoptosis. Int. J. Cancer, 2009, 124(3), 511-515.
5. Lowe, S.W.; Cepero, E.; Evan, G. Intrinsic tumour suppression. Nature, 2004, 432(7015), 307-315.
6. Degterev, A.; Hitomi, J.; Germscheid, M.; Ch'en, I.L.; Korkina, O.; Teng, X.; Abbott, D.; Cuny, G.D.; Yuan, C.; Wagner, G.; Hedrick, S.M.; Gerber, S.A.; Lugovskoy, A.; Yuan, J. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol, 2008, 4(5), 313-321.
7. Taylor, R.C.; Cullen, S.P.; Martin, S.J. Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol., 2008, 9(3), 231-241.
8. Degterev, A.; Boyce, M.; Yuan, J. A decade of caspases. Oncogene, 2003, 22(53), 8543-8567.
9. Ashkenazi, A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev., 2008, 19(3-4), 325-331.
10. Adams, J.M.; Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene, 2007, 26(9), 1324-1337.
11. Kroemer, G.; Galluzzi, L.; Brenner, C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev., 2007, 87(1), 99-163.
12. LaCasse, E.C.; Mahoney, D.J.; Cheung, H.H.; Plenchette, S.; Baird, S.; Korneluk, R.G. IAP-targeted therapies for cancer. Oncogene, 2008, 27(48), 6252-6275.
13. Okada, H.; Mak, T.W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer, 2004, 4(8), 592-603.
14. Maiuri, M.C.; Zalckvar, E.; Kimchi, A.; Kroemer, G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell Biol., 2007, 8(9), 741-752.
15. Kirkegaard, T.; Jaattela, M. Lysosomal involvement in cell death and cancer. Biochim. Biophys. Acta, 2009, 1793(4), 746-754.
16. Festjens, N.; Van den Berghe, T.; Vandenabeele, P. Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. Biochim. Biophys. Acta, 2006, 1757(9-10), 1371-1387.
17. Kondo, Y.; Kanzawa, T.; Sawaya, R.; Kondo, S. The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer, 2005, 5(9), 726-734.
18. Pervaiz, S. Resveratrol: from grapevines to mammalian biology. FASEB J., 2003, 17(14), 1975-1985.
19. Gusman, J.; Malonne, H.; Atassi, G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis, 2001, 22(8), 1111-1117.
20. Pervaiz, S.; Holme, A.L. Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal, 2009, 11(11), 2851-2897.
21. Stivala, L.A.; Savio, M.; Carafoli, F.; Perucca, P.; Bianchi, L.; Maga, G.; Forti, L.; Pagnoni, U.M.; Albini, A.; Prosperi, E.; Vannini, V. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J. Biol. Chem., 2001, 276(25), 22586-22594.
22. Zykova, T.A.; Zhu, F.; Zhai, X.; Ma, W.Y.; Ermakova, S.P.; Lee, K.W.; Bode, A.M.; Dong, Z. Resveratrol directly targets COX-2 to inhibit carcinogenesis. Mol. Carcinog., 2008, 47(10), 797-805.
23. Colin, D.; Limagne, E.; Jeanningros, S.; Jacquel, A.; Lizard, G.; Athias, A.; Gambert, P.; Hichami, A.; Latruffe, N.; Solary, E.; Delmas, D. Endocytosis of resveratrol via lipid rafts and activation of downstream signaling pathways in cancer cells. Cancer Prev Res (Phila), 2011, 4(7), 1095-1106.
24. Reis-Sobreiro, M.; Gajate, C.; Mollinedo, F. Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions. Oncogene, 2009, 28(36), 3221-3234.
25. Delmas, D.; Rebe, C.; Micheau, O.; Athias, A.; Gambert, P.; Grazide, S.; Laurent, G.; Latruffe, N.; Solary, E. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene, 2004, 23(55), 8979-8986.
26. Delmas, D.; Rebe, C.; Lacour, S.; Filomenko, R.; Athias, A.; Gambert, P.; Cherkaoui-Malki, M.; Jannin, B.; Dubrez-Daloz, L.; Latruffe, N.; Solary, E. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J. Biol. Chem., 2003, 278(42), 41482-41490.
27. Cal, C.; Garban, H.; Jazirehi, A.; Yeh, C.; Mizutani, Y.; Bonavida, B. Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities. Curr Med Chem Anti-Canc Agents 3(4):253-62, 2003, 3(2), 77-93.
28. Kraft, T.E.; Parisotto, D.; Schempp, C.; Efferth, T. Fighting cancer with red wine? Molecular mechanisms of resveratrol. Crit. Rev. Food Sci. Nutr., 2009, 49(9), 782-799.
29. Fulda, S.; Debatin, K.M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res., 2004, 64(1), 337-346.
30. Singh, S.K.; Moretta, D.; Almaguel, F.; Wall, N.R.; De Leon, M.; De Leon, D. Differential effect of proIGF-II and IGF-II on resveratrol induced cell death by regulating survivin cellular localization and mitochondrial depolarization in breast cancer cells. Growth Factors, 2007, 25(6), 363-372.
31. Hayashibara, T.; Yamada, Y.; Nakayama, S.; Harasawa, H.; Tsuruda, K.; Sugahara, K.; Miyanishi, T.; Kamihira, S.; Tomonaga, M.; Maita, T. Resveratrol induces downregulation in survivin expression and apoptosis in HTLV-1-infected cell lines: a prospective agent for adult T cell leukemia chemotherapy. Nutr Cancer, 2002, 44(2), 193-201.
32. Bhardwaj, A.; Sethi, G.; Vadhan-Raj, S.; Bueso-Ramos, C.; Takada, Y.; Gaur, U.; Nair, A.S.; Shishodia, S.; Aggarwal, B.B. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood, 2007, 109(6), 2293-2302.
33. Shankar, S.; Chen, Q.; Siddiqui, I.; Sarva, K.; Srivastava, R.K. Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4', 5 tri-hydroxystilbene): molecular mechanisms and therapeutic potential. J Mol Signal, 2007, 2, 7.
34. Fulda, S.; Debatin, K.-M. Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling. Eur. J. Cancer, 2005, 41(5), 786-798.
35. Wang, R.H.; Zheng, Y.; Kim, H.S.; Xu, X.; Cao, L.; Luhasen, T.; Lee, M.H.; Xiao, C.; Vassilopoulos, A.; Chen, W.; Gardner, K.; Man, Y.G.; Hung, M.C.; Finkel, T.; Deng, C.X. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol. Cell, 2008, 32(1), 11-20.
36. Zhao, W.; Bao, P.; Qi, H.; You, H. Resveratrol down-regulates survivin and induces apoptosis in human multidrug-resistant SPCA-1/CDDP cells. Oncol. Rep., 2010, 23(1), 279-286.
37. Ling, X.; He, X.; Apontes, P.; Cao, F.; Azrak, R.G.; Li, F. Enhancing effectiveness of the MDR-sensitive compound T138067 using advanced treatment with negative modulators of the drug-resistant protein survivin. Am J Transl Res, 2009, 1(4), 393-405.
38. Harikumar, K.B.; Kunnumakkara, A.B.; Sethi, G.; Diagaradjane, P.; Anand, P.; Pandey, M.K.; Gelovani, J.; Krishnan, S.; Guha, S.; Aggarwal, B.B. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int. J. Cancer, 2010, 127(2), 257-268.
39. Yu, L.J.; Wu, M.L.; Li, H.; Chen, X.Y.; Wang, Q.; Sun, Y.; Kong, Q.Y.; Liu, J. Inhibition of STAT3 expression and signaling in resveratrol-differentiated medulloblastoma cells. Neoplasia, 2008, 10(7), 736-744.
40. Aziz, M.H.; Afaq, F.; Ahmad, N. Prevention of ultraviolet-B radiation damage by resveratrol in mouse skin is mediated via modulation in survivin. Photochem Photobiol, 2005, 81(1), 25-31.
41. Roy, P.; Kalra, N.; Prasad, S.; George, J.; Shukla, Y. Chemopreventive potential of resveratrol in mouse skin tumors through regulation of mitochondrial and PI3K/AKT signaling pathways. Pharm Res, 2009, 26(1), 211-217.
42. Jazirehi, A.R.; Bonavida, B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol. Cancer Ther., 2004, 3(1), 71-84.
43. Kotha, A.; Sekharam, M.; Cilenti, L.; Siddiquee, K.; Khaled, A.; Zervos, A.S.; Carter, B.; Turkson, J.; Jove, R. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol. Cancer Ther., 2006, 5(3), 621-629.
44. Gledhill, J.R.; Montgomery, M.G.; Leslie, A.G.; Walker, J.E. Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc Natl Acad Sci U S A, 2007, 104(34), 13632-13637.
45. Lagouge, M.; Argmann, C.; Gerhart-Hines, Z.; Meziane, H.; Lerin, C.; Daussin, F.; Messadeq, N.; Milne, J.; Lambert, P.; Elliott, P.; Geny, B.; Laakso, M.; Puigserver, P.; Auwerx, J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 2006, 127(6), 1109-1122.
46. Jeong, S.H.; Jo, W.S.; Song, S.; Suh, H.; Seol, S.Y.; Leem, S.H.; Kwon, T.K.; Yoo, Y.H. A novel resveratrol derivative, HS1793, overcomes the resistance conferred by Bcl-2 in human leukemic U937 cells. Biochem. Pharmacol., 2009, 77(8), 1337-1347.
47. Morrison, D.K. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol., 2009, 19(1), 16-23.
48. Clement, M.V.; Hirpara, J.L.; Chawdhury, S.H.; Pervaiz, S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood, 1998, 92(3), 996-1002.
49. Karin, M.; Cao, Y.; Greten, F.R.; Li, Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer, 2002, 2(4), 301-310.
50. Hayden, M.S.; Ghosh, S. Shared principles in NF-kappaB signaling. Cell, 2008, 132(3), 344-362.
51. Holmes-McNary, M.; Baldwin, A.S., Jr. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res., 2000, 60(13), 3477-3483.
52. Manna, S.K.; Mukhopadhyay, A.; Aggarwal, B.B. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol., 2000, 164(12), 6509-6519.
53. Yeung, F.; Hoberg, J.E.; Ramsey, C.S.; Keller, M.D.; Jones, D.R.; Frye, R.A.; Mayo, M.W. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. Embo J., 2004, 23(12), 2369-2380.
54. Howitz, K.T.; Bitterman, K.J.; Cohen, H.Y.; Lamming, D.W.; Lavu, S.; Wood, J.G.; Zipkin, R.E.; Chung, P.; Kisielewski, A.; Zhang, L.L.; Scherer, B.; Sinclair, D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 2003, 425(6954), 191-196.
55. Blander, G.; Guarente, L. The Sir2 family of protein deacetylases. Annu. Rev. Biochem., 2004, 73, 417-435.
56. Yu, H.B.; Zhang, H.F.; Zhang, X.; Li, D.Y.; Xue, H.Z.; Pan, C.E.; Zhao, S.H. Resveratrol inhibits VEGF expression of human hepatocellular carcinoma cells through a NF-kappa B-mediated mechanism. Hepatogastroenterology, 2011, 57(102-103), 1241-1246.
57. Banerjee, S.; Bueso-Ramos, C.; Aggarwal, B.B. Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res., 2002, 62(17), 4945-4954.
58. Bishayee, A.; Waghray, A.; Barnes, K.F.; Mbimba, T.; Bhatia, D.; Chatterjee, M.; Darvesh, A.S. Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. Pharm Res, 2010, 27(6), 1080-1091.
59. Kang, S.S.; Cuendet, M.; Endringer, D.C.; Croy, V.L.; Pezzuto, J.M.; Lipton, M.A. Synthesis and biological evaluation of a library of resveratrol analogues as inhibitors of COX-1, COX-2 and NFkappaB. Bioorg. Med. Chem., 2009, 17(3), 1044-1054.
60. Estrov, Z.; Shishodia, S.; Faderl, S.; Harris, D.; Van, Q.; Kantarjian, H.M.; Talpaz, M.; Aggarwal, B.B. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood, 2003, 102(3), 987-995.
61. Rambaldi, A.; Torcia, M.; Bettoni, S.; Vannier, E.; Barbui, T.; Shaw, A.R.; Dinarello, C.A.; Cozzolino, F. Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. Blood, 1991, 78(12), 3248-3253.
62. Roy, P.; Kalra, N.; Nigam, N.; George, J.; Ray, R.S.; Hans, R.K.; Prasad, S.; Shukla, Y. Resveratrol enhances ultraviolet B-induced cell death through nuclear factor-kappaB pathway in human epidermoid carcinoma A431 cells. Biochem. Biophys. Res. Commun., 2009, 384(2), 215-220.
63. Shaw, R.J.; Cantley, L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature, 2006, 441(7092), 424-430.
64. She, Q.-B.; Huang, C.; Zhang, Y.; Dong, Z. Involvement of c-jun NH(2)-terminal kinases in resveratrol-induced activation of p53 and apoptosis. Mol. Carcinog., 2002, 33(4), 244-250.
65. Kaneuchi, M.; Sasaki, M.; Tanaka, Y.; Yamamoto, R.; Sakuragi, N.; Dahiya, R. Resveratrol suppresses growth of Ishikawa cells through down-regulation of EGF. Int. J. Oncol., 2003, 23(4), 1167-1172.
66. Lee, M.H.; Choi, B.Y.; Kundu, J.K.; Shin, Y.K.; Na, H.K.; Surh, Y.J. Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model: eukaryotic elongation factor 1A2 as a potential target. Cancer Res., 2009, 69(18), 7449-7458.
67. Pozo-Guisado, E.; Lorenzo-Benayas, M.J.; Fernandez-Salguero, P.M. Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation. Int. J. Cancer, 2004, 109(2), 167-173.
68. Jiang, H.; Shang, X.; Wu, H.; Gautam, S.C.; Al-Holou, S.; Li, C.; Kuo, J.; Zhang, L.; Chopp, M. Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. J. Exp. Ther. Oncol., 2009, 8(1), 25-33.
69. Zamin, L.L.; Filippi-Chiela, E.C.; Dillenburg-Pilla, P.; Horn, F.; Salbego, C.; Lenz, G. Resveratrol and quercetin cooperate to induce senescence-like growth arrest in C6 rat glioma cells. Cancer Sci, 2009, 100(9), 1655-1662.
70. He, X.; Wang, Y.; Zhu, J.; Orloff, M.; Eng, C. Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling. Cancer Lett., 2011, 301(2), 168-176.
71. O'Reilly, K.E.; Rojo, F.; She, Q.-B.; Solit, D.; Mills, G.B.; Smith, D.; Lane, H.; Hofmann, F.; Hicklin, D.J.; Ludwig, D.L.; Baselga, J.; Rosen, N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res., 2006, 66(3), 1500-1508.
72. Yu, R.; Hebbar, V.; Kim, D.W.; Mandlekar, S.; Pezzuto, J.M.; Kong, A.N. Resveratrol inhibits phorbol ester and UV-induced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways. Mol. Pharmacol., 2001, 60(1), 217-224.
73. Huang, C.; Ma, W.Y.; Goranson, A.; Dong, Z. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis, 1999, 20(2), 237-242.
74. She, Q.B.; Bode, A.M.; Ma, W.Y.; Chen, N.Y.; Dong, Z. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res., 2001, 61(4), 1604-1610.
75. Miloso, M.; Bertelli, A.A.; Nicolini, G.; Tredici, G. Resveratrolinduced activation of the mitogen-activated protein kinases, ERK1 and ERK2, in human neuroblastoma SH-SY5Y cells. Neurosci Lett, 1999, 264(1-3), 141-144.
76. Madan, E.; Prasad, S.; Roy, P.; George, J.; Shukla, Y. Regulation of apoptosis by resveratrol through JAK/STAT and mitochondria mediated pathway in human epidermoid carcinoma A431 cells. Biochem. Biophys. Res. Commun., 2008, 377(4), 1232-1237.
77. Li, H.; Wu, W.K.; Zheng, Z.; Che, C.T.; Yu, L.; Li, Z.J.; Wu, Y.C.; Cheng, K.W.; Yu, J.; Cho, C.H.; Wang, M. 2,3',4,4',5'Pentamethoxy-trans-stilbene, a resveratrol derivative, is a potent inducer of apoptosis in colon cancer cells via targeting microtubules. Biochem. Pharmacol., 2009, 78(9), 1224-1232.
78. Yang, Y.T.; Weng, C.J.; Ho, C.T.; Yen, G.C. Resveratrol analog-3,5,4'-trimethoxy-trans-stilbene inhibits invasion of human lung adenocarcinoma cells by suppressing the MAPK pathway and decreasing matrix metalloproteinase-2 expression. Mol Nutr Food Res, 2009, 53(3), 407-416.
79. Dong, L.F.; Jameson, V.J.; Tilly, D.; Prochazka, L.; Rohlena, J.; Valis, K.; Truksa, J.; Zobalova, R.; Mahdavian, E.; Kluckova, K.; Stantic, M.; Stursa, J.; Freeman, R.; Witting, P.K.; Norberg, E.; Goodwin, J.; Salvatore, B.A.; Novotna, J.; Turanek, J.; Ledvina, M.; Hozak, P.; Zhivotovsky, B.; Coster, M.J.; Ralph, S.J.; Smith, R.A.; Neuzil, J. Mitochondrial targeting of alpha-tocopheryl succinate enhances its pro-apoptotic efficacy: A new paradigm for effective cancer therapy. Free Radic Biol Med, 2011, 50(11), 1546-1555.
80. Biasutto, L.; Mattarei, A.; Marotta, E.; Bradaschia, A.; Sassi, N.; Garbisa, S.; Zoratti, M.; Paradisi, C. Development of mitochondria-targeted derivatives of resveratrol. Bioorg. Med. Chem. Lett., 2008, 18(20), 5594-5597.
81. Boocock, D.J.; Faust, G.E.; Patel, K.R.; Schinas, A.M.; Brown, V.A.; Ducharme, M.P.; Booth, T.D.; Crowell, J.A.; Perloff, M.; Gescher, A.J.; Steward, W.P.; Brenner, D.E. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev., 2007, 16(6), 1246-1252.
82. Tili, E.; Michaille, J.J. Resveratrol, MicroRNAs, Inflammation, and Cancer. J. Nucleic Acids, 2011, 2011, 102-431.